

Freedom of Information Request: Our Reference CTMUHB_32_22

You asked:

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Apremilast**
- **Bimekizumab**
- **Brodalumab**
- **Certolizumab**
- **Dimethyl fumarate**
- **Etanercept - Enbrel**
- **Etanercept Biosimilar**
- **Guselkumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Ixekizumab**
- **Risankizumab**
- **Secukinumab**
- **Tildrakizumab**
- **Ustekinumab**

Please see provided below a table populated with the data that Medicines Management are able to provide in relation to Q1. The period the data relates to is the latest 3 months available as follows:

- Hospital dispensed prescriptions – November 21, December 21 and January 22 and
- Community pharmacy dispensed prescriptions – September 21, October 21 and November 21.

Please note the majority of patients requiring treatment with the medicines outlined in your request will be referred into the services of a neighbouring Health Board; for Merthyr & Cynon and Rhondda, Taff Ely Localities patients are referred to Cardiff and the Vale UHB and for Bridgend Localities patients treatments are serviced by Swansea Bay UHB. Hopefully, this will provide an explanation as to why our patient numbers are low for the medicines relating to your above enquiry.

	Hospital Dispensed	WP10HP's - Community Pharmacy Dispensed
Adalimumab - Humira	**	
Adalimumab Biosimilar	**	
Apremilast	**	52
Certolizumab		
Dimethyl fumarate		
Etanercept - Enbrel		

Etanercept Biosimilar		
Infliximab - Remicade		
Infliximab Biosimilar	**	
Ixekizumab		
Secukinumab		
Ustekinumab		
Bimekizumab		
Brodalumab		
Guselkumab		
Risankizumab		
Tildrakizumab		

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q2. How many patients have been treated for Psoriasis ONLY in the last three months with the following:

- **Ciclosporin**
- **Methotrexate - any form and strength**
- **Methotrexate injections 15mg and above**

Patient level details are not captured on our Medicines Management system. Therefore, we are unable to provide the number of patients treated for Psoriasis.

The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.